ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Currently, the most effective and best tolerated drug against CML is imatinib mesylate (Gleevec® or Glivec®, previously known as STI-571), a selective BCR-ABL tyrosine kinase inhibitor [2].